Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction

The IC-HOT study

Shukri W. David, Zubair A. Khan, Nainesh C. Patel, D. Christopher Metzger, Frances O. Wood, Hal S. Wasserman, Amir S. Lotfi, Ivan D. Hanson, Simon R. Dixon, Thomas A. LaLonde, Philippe Genereux, Melek Ozgu Ozan, Akiko Maehara, Gregg W. Stone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: In the randomized AMIHOT-II trial, supersaturated oxygen [SSO 2 ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial infarction (STEMI) but resulted in a numerically higher incidence of safety events. Objectives: The IC-HOT study evaluated the safety of SSO 2 therapy selectively delivered to the left main coronary artery (LMCA) for 60 minutes after PCI in patients with anterior STEMI. Methods: SSO 2 therapy was administered to the LMCA after stent implantation in 100 patients with anterior STEMI and proximal or mid-LAD occlusion presenting within 6 hours of symptom onset. The primary endpoint was the 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding) compared against an objective performance goal of 10.7%. Cardiac magnetic resonance imaging was performed at 4 and 30 days to assess infarct size. Results: SSO 2 delivery was successful in 98% of patients. NACE at 30 days occurred 7.1% of patients (meeting the primary safety endpoint of the study); there were no deaths, only one stent thrombosis and one case of severe heart failure. Median [interquartile range] infarct size was 24.1% [14.4%, 31.6%] at 4 days and 19.4% [8.8%, 28.9%] at 30 days. Conclusion: Following primary PCI in acute anterior STEMI, infusion of SSO 2 via the LMCA was feasible and was associated with a favorable early safety profile.

Original languageEnglish (US)
Pages (from-to)882-890
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Volume93
Issue number5
DOIs
StatePublished - Apr 1 2019

Fingerprint

Myocardial Infarction
Oxygen
Percutaneous Coronary Intervention
Stents
Safety
Coronary Vessels
Thrombosis
Heart Failure
Therapeutics
Catheters
Arteries
Magnetic Resonance Imaging
Hemorrhage
ST Elevation Myocardial Infarction
Incidence

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

David, S. W., Khan, Z. A., Patel, N. C., Metzger, D. C., Wood, F. O., Wasserman, H. S., ... Stone, G. W. (2019). Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction: The IC-HOT study. Catheterization and Cardiovascular Interventions, 93(5), 882-890. https://doi.org/10.1002/ccd.27905
David, Shukri W. ; Khan, Zubair A. ; Patel, Nainesh C. ; Metzger, D. Christopher ; Wood, Frances O. ; Wasserman, Hal S. ; Lotfi, Amir S. ; Hanson, Ivan D. ; Dixon, Simon R. ; LaLonde, Thomas A. ; Genereux, Philippe ; Ozan, Melek Ozgu ; Maehara, Akiko ; Stone, Gregg W. / Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction : The IC-HOT study. In: Catheterization and Cardiovascular Interventions. 2019 ; Vol. 93, No. 5. pp. 882-890.
@article{ea4722936b244ef09732eae28c96b459,
title = "Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction: The IC-HOT study",
abstract = "Background: In the randomized AMIHOT-II trial, supersaturated oxygen [SSO 2 ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial infarction (STEMI) but resulted in a numerically higher incidence of safety events. Objectives: The IC-HOT study evaluated the safety of SSO 2 therapy selectively delivered to the left main coronary artery (LMCA) for 60 minutes after PCI in patients with anterior STEMI. Methods: SSO 2 therapy was administered to the LMCA after stent implantation in 100 patients with anterior STEMI and proximal or mid-LAD occlusion presenting within 6 hours of symptom onset. The primary endpoint was the 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding) compared against an objective performance goal of 10.7{\%}. Cardiac magnetic resonance imaging was performed at 4 and 30 days to assess infarct size. Results: SSO 2 delivery was successful in 98{\%} of patients. NACE at 30 days occurred 7.1{\%} of patients (meeting the primary safety endpoint of the study); there were no deaths, only one stent thrombosis and one case of severe heart failure. Median [interquartile range] infarct size was 24.1{\%} [14.4{\%}, 31.6{\%}] at 4 days and 19.4{\%} [8.8{\%}, 28.9{\%}] at 30 days. Conclusion: Following primary PCI in acute anterior STEMI, infusion of SSO 2 via the LMCA was feasible and was associated with a favorable early safety profile.",
author = "David, {Shukri W.} and Khan, {Zubair A.} and Patel, {Nainesh C.} and Metzger, {D. Christopher} and Wood, {Frances O.} and Wasserman, {Hal S.} and Lotfi, {Amir S.} and Hanson, {Ivan D.} and Dixon, {Simon R.} and LaLonde, {Thomas A.} and Philippe Genereux and Ozan, {Melek Ozgu} and Akiko Maehara and Stone, {Gregg W.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/ccd.27905",
language = "English (US)",
volume = "93",
pages = "882--890",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "5",

}

David, SW, Khan, ZA, Patel, NC, Metzger, DC, Wood, FO, Wasserman, HS, Lotfi, AS, Hanson, ID, Dixon, SR, LaLonde, TA, Genereux, P, Ozan, MO, Maehara, A & Stone, GW 2019, 'Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction: The IC-HOT study', Catheterization and Cardiovascular Interventions, vol. 93, no. 5, pp. 882-890. https://doi.org/10.1002/ccd.27905

Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction : The IC-HOT study. / David, Shukri W.; Khan, Zubair A.; Patel, Nainesh C.; Metzger, D. Christopher; Wood, Frances O.; Wasserman, Hal S.; Lotfi, Amir S.; Hanson, Ivan D.; Dixon, Simon R.; LaLonde, Thomas A.; Genereux, Philippe; Ozan, Melek Ozgu; Maehara, Akiko; Stone, Gregg W.

In: Catheterization and Cardiovascular Interventions, Vol. 93, No. 5, 01.04.2019, p. 882-890.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction

T2 - The IC-HOT study

AU - David, Shukri W.

AU - Khan, Zubair A.

AU - Patel, Nainesh C.

AU - Metzger, D. Christopher

AU - Wood, Frances O.

AU - Wasserman, Hal S.

AU - Lotfi, Amir S.

AU - Hanson, Ivan D.

AU - Dixon, Simon R.

AU - LaLonde, Thomas A.

AU - Genereux, Philippe

AU - Ozan, Melek Ozgu

AU - Maehara, Akiko

AU - Stone, Gregg W.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: In the randomized AMIHOT-II trial, supersaturated oxygen [SSO 2 ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial infarction (STEMI) but resulted in a numerically higher incidence of safety events. Objectives: The IC-HOT study evaluated the safety of SSO 2 therapy selectively delivered to the left main coronary artery (LMCA) for 60 minutes after PCI in patients with anterior STEMI. Methods: SSO 2 therapy was administered to the LMCA after stent implantation in 100 patients with anterior STEMI and proximal or mid-LAD occlusion presenting within 6 hours of symptom onset. The primary endpoint was the 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding) compared against an objective performance goal of 10.7%. Cardiac magnetic resonance imaging was performed at 4 and 30 days to assess infarct size. Results: SSO 2 delivery was successful in 98% of patients. NACE at 30 days occurred 7.1% of patients (meeting the primary safety endpoint of the study); there were no deaths, only one stent thrombosis and one case of severe heart failure. Median [interquartile range] infarct size was 24.1% [14.4%, 31.6%] at 4 days and 19.4% [8.8%, 28.9%] at 30 days. Conclusion: Following primary PCI in acute anterior STEMI, infusion of SSO 2 via the LMCA was feasible and was associated with a favorable early safety profile.

AB - Background: In the randomized AMIHOT-II trial, supersaturated oxygen [SSO 2 ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial infarction (STEMI) but resulted in a numerically higher incidence of safety events. Objectives: The IC-HOT study evaluated the safety of SSO 2 therapy selectively delivered to the left main coronary artery (LMCA) for 60 minutes after PCI in patients with anterior STEMI. Methods: SSO 2 therapy was administered to the LMCA after stent implantation in 100 patients with anterior STEMI and proximal or mid-LAD occlusion presenting within 6 hours of symptom onset. The primary endpoint was the 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding) compared against an objective performance goal of 10.7%. Cardiac magnetic resonance imaging was performed at 4 and 30 days to assess infarct size. Results: SSO 2 delivery was successful in 98% of patients. NACE at 30 days occurred 7.1% of patients (meeting the primary safety endpoint of the study); there were no deaths, only one stent thrombosis and one case of severe heart failure. Median [interquartile range] infarct size was 24.1% [14.4%, 31.6%] at 4 days and 19.4% [8.8%, 28.9%] at 30 days. Conclusion: Following primary PCI in acute anterior STEMI, infusion of SSO 2 via the LMCA was feasible and was associated with a favorable early safety profile.

UR - http://www.scopus.com/inward/record.url?scp=85054051274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054051274&partnerID=8YFLogxK

U2 - 10.1002/ccd.27905

DO - 10.1002/ccd.27905

M3 - Article

VL - 93

SP - 882

EP - 890

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 5

ER -